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Background. End-stage renal disease (ESRD) is a state of
microinflammation, with increased activation of cytokines and
augmented oxidative stress. While peripheral blood mononu-
clear cells are an established source of reactive oxygen species
and inflammatory cytokines during hemodialysis (HD), skeletal
muscle is also capable of generating these biomolecules.
Methods. Femoral arterio-venous (A-V) balance of
interleukin-1 (IL-1), IL-6, IL-10, tumor necrosis factor-a
(TNF-a), malonyldialdehyde (MDA), and carbonyl protein
(CP) were measured in 17 ESRD patients and 9 healthy volun-
teers. ESRD patients were studied before (pre-HD) and during
HD. mRNA levels of cytokines, heme oxygenase-1 (HO-1), and
suppressors of cytokine signaling-2 (SOCS-2) were quantitated
in the skeletal muscle by real-time polymerase chain reaction
(PCR).
Results. Arterial concentration of MDA (pmol/mL) was
higher pre-HD (325.5 ± 19.6) compared to controls (267.7 ±
14.7), but decreased intradialysis (248.8 ± 16.1) (P < 0.01). Dial-
ysis clearance of MDA was 16.9 ± 3.1 mL/min. CP concentration
(nmol/mg protein) in the artery was significantly higher pre-HD
(2.29 ± 0.09) than in controls (1.92 ± 0.05), and remained sta-
ble during HD (2.23 ± 0.07). Plasma cytokines increased to a
variable degree in the artery and vein during HD. A-V balance
studies demonstrated that the MDA (17.8%) and CP (5.1%)
concentrations increased significantly in the vein intradialysis.
Venous concentration of IL-6 was higher than that in the artery
during dialysis (16.27 ± 2.42 vs. 11.29 ± 2.17 pg/dL, P < 0.01).
mRNA levels of IL-6 (0.028 ± 0.02 vs. 6.69 ± 0.21), HO-1 (0.96
± 0.01 vs. 5.08 ± 1.11), and SOCS-2 (0.63 ± 0.12 vs. 0.82 ± 0.14)
in the muscle increased during HD (P < 0.01). Immunohisto-
chemical studies confirmed the increase in IL-6 protein in the
skeletal muscle during HD. The intradialytic increase in IL-1,
IL-10, and TNF-a gene expression was not significant.
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Conclusion. Skeletal muscle may also contribute to the cir-
culating plasma IL-6 and increased oxidative stress during HD.
Inflammation coexists with increased oxidative stress
in end-stage renal disease (ESRD). Overwhelming pro-
duction of free radicals, and lipid and protein oxidation
byproducts could lead to organ damage. Carbonyl protein
(CP) is a marker of oxidative damage in cells and tissue
proteins [1]. Malonyldialdehyde (MDA) is a water solu-
ble lipid peroxidation product that is partially excreted
by the kidney [2]. Oxidative stress is increased in patients
with reduced renal function [3]. It is unknown whether
elevated markers of oxidative stress reflect increased gen-
eration or reduced metabolic clearance. While some in-
vestigators have demonstrated exacerbation of the flux of
free radicals with initiation of renal replacement therapy
[4], others have observed no change [5] or decrease [6]
in indices of oxidative stress during hemodialysis (HD).
These discordant results are the reflection of differences
in biocompatibility of the dialysis therapy [7], use of dis-
parate markers of oxidative stress [6], and failure to take
in to account the intradialytic loss of the biomolecules in
the dialysate [6].
Oxygen-derived free radicals are produced during mi-
tochondrial respiration in the skeletal muscle and by the
activated peripheral blood mononuclear cells (PBMC).
Blood membrane interaction during HD promotes se-
cretion of cytokines and also formation to reactive oxy-
gen species (ROS) by the PBMC. Respiratory chain
is a powerful source of oxidative stress, with 1% to
4% of oxygen reacting with the respiratory chain in-
completely reduced to ROS [8]. Impaired mitochondrial
function [9] and decreased antioxidant capacity [10] in
ESRD could potentially augment the oxidative stress in
ESRD. Oxidants may amplify the inflammatory cascade
via activation of the nuclear factor-jB (NF-jB) path-
way [11]. Human skeletal muscle has the inherent ability
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to express interleukin-6 (IL-6) [12]. IL-6 is produced
in response to diverse stimuli and mediates pleiotropic
actions, including acute phase response, immune mod-
ulation, hematopoisis, and metabolic regulation. Heme
oxygenase-1 (HO-1) is a heat shock protein that is ex-
pressed in the skeletal muscle. It plays an important role
in the cellular defense against oxidative stress and the
detrimental effects of proinflammatory cytokines [13].
The suppressors of cytokine signaling (SOCS) family of
proteins play key roles in the negative regulation of cy-
tokine signal transduction [14]. The SOCS family consists
of 8 proteins: cytokine-inducible SH2 protein (CIS) and
SOCS1-SOCS7. The expressions of SOCS1 to 3 and CIS
are induced by cytokine or growth factors, resulting in the
inhibition of JAK/STAT-mediated cytokine signaling by
a negative feedback loop [15, 16].
We hypothesized that HD induces generation of ROS
and release of cytokines from the skeletal muscle. In
order to test the hypothesis, we measured the femoral
arterio-venous (A-V) balance of MDA, CP, and repre-
sentative cytokines, IL-1, IL-6, IL-10, and tumor necro-
sis factor-a (TNF-a) across the leg in 17 ESRD patients
and 9 healthy volunteers. We also simultaneously quanti-
tated the mRNA levels of the respective cytokines, HO-1
and SOCS-2, in the skeletal muscle. ESRD patients were
studied before (pre-HD) and during HD. The changes in
markers of oxidative stress were interpreted in the con-
text of removal by dialysis. mRNA levels of IL-6, HO-1,
and SOCS-2 in the skeletal muscle increased intradialysis,
which was associated with a more pronounced increase in
the concentrations of MDA, CP, and IL-6 in the femoral
vein than in the artery.
METHODS
Seventeen ESRD patients and 9 healthy volunteers
were studied. The study was approved by the Human
Research Review Committee at the University of New
Mexico. Informed consent was obtained from all the par-
ticipants. Patients were admitted to the General Clinical
Research Center at the University of New Mexico the day
before the experiment. All the studies were performed in
a postabsorptive state, after overnight fast. The femoral
artery and vein were cannulated on the same side, taking
all aseptic precautions. In ESRD patients, blood samples
were collected from the femoral artery and vein prior to
initiation of HD (pre-HD), at midpoint of HD (mid-HD),
and during the last 10 minutes of HD (end-HD). Skele-
tal muscle biopsies were also obtained at the same time
points. In controls, muscle biopsy and A-V balance study
was performed only once.
Hemodialysis
Only ESRD patients underwent HD. The patients’
standard dialysis prescription was used, except that all
the patients received 4 hours of dialysis. Dialysate com-
position was sodium (Na+) 139 mEq/L, bicarbonate
(HCO3) 35 mEq/L, calcium (Ca++) 2.5 mEq/L, mag-
nesium (Mg++) 1 mEq/L, dextrose 200 mg/dL, and
potassium (K+) (per patient’s need). A new polysulfone
membrane (Hemoflow, F70; Fresenius, Walnut Creek,
CA, USA) was used. Anticoagulation was not used dur-
ing dialysis to minimize the risk of bleeding. While the
patient’s regular erythropoietin dose was continued, iron
infusion was avoided. Representative dialysate samples
were collected every 10 minutes in a sterile container.
The spent dialysate sample was mixed thoroughly, and a
sample was taken and stored at −80◦C for future analysis.
Muscle biopsy
Muscle biopsies were taken from the lateral portion
of vastus lateralis about 20 cm above the knee using
Bergstrom biopsy needle. Approximately 30 to 50 mg of
muscle tissue was obtained during each biopsy. Fat and
connective tissue were completely removed and the sam-
ple immediately frozen in liquid nitrogen and stored at
−80◦C for future analysis. During repeat biopsies care
was taken to obtain samples from sites away from the
initial site.
Assay for IL-1, IL-6, IL-10, and TNF-a
Cytokines were measured in plasma samples using
commercially available enzyme-linked immunosorbent
assay (ELISA) kits (R&D System, Minneapolis, MN,
USA) according to the manufacturer’s directions. Assays
were performed in duplicates and the mean of the 2 mea-
surements was used. The inter- and intraassay CV% for
each cytokine were <6%.
Measurement of plasma MDA and CP
MDA was measured using ion exclusion and reverse-
phase Shodex KC-811 column (Waters, Milford, MA,
USA) with detector set at 532 nm [3]. The day to day vari-
ation in standard assays of MDA was <7%. Each plasma
sample was assayed in duplicate and variation between
duplicate samples was <9%.
The hemodialysis clearance of MDA was calculated by
the following equation:
MDA clearance = (volume of dialysate
× concentration in dialysate)/
area under the curve.
Area under the curve was calculated by the trapezoidal
rule using the software WinNonLin (version 4.1; Moun-
tain View, CA, USA).
CP was measured as we described earlier [3]. Briefly,
duplicate samples were prepared by adding 10 lL of
plasma to 1.0 mL of phosphate-buffered saline (PBS)
in 13 × 100 mm tube. One of the duplicate sample
was treated with 200 lL of 2,4 Di-nitro phenylhydrazine
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(DNPH) in 2 N hydrochloric acid (HCl). To the other
sample, 200 lL of 2 N HCl was added, which was used
as a blank. The mixture was incubated at room temper-
ature for 1 hour, followed by the addition of 1.2 mL of
20% TCA. The samples were then incubated in ice for
10 minutes and centrifuged at 600g, 40◦C for 10 min-
utes, and the supernatant discarded. The protein pellet
was washed 2 times with 3 mL of ethyl alcohol:ethyl ac-
etate (1:1, v/v) and dried under nitrogen gas. The pro-
tein pellet was dissolved in 1 mL of 10 mmol/L sodium
phosphate (pH 6.8) containing 3% sodium dodecyl sul-
fate (SDS). Each sample was then scanned from 320 to
410 nm in UV/Vis Spectrophotometer (Beckman Du-640;
Beckman, Corona, CA, USA) against a duplicate blank
treated with HCl. The concentration of carbonyl groups
was calculated from the absorbance spectrum, with the
extinction coefficient for aliphatic hydrazone derivatives
assayed at 360 nm. The final data are expressed as nmol
of carbonyl groups per mg of protein. The CV% for the
assay was <6%.
Real-time PCR for IL-1, IL-6, IL-10, TNF-a, HO-1,
and SOCS-2
Muscle biopsy material (20 mg) was homoge-
nized in Qiagen’s RNeasy lysis buffer containing 2-
mercaptoethanol (Qiagen, Valencia, CA, USA) at room
temperature. RNA was isolated and purified using the
Qiagen RNeasy mini protocol for isolation of total
RNA from muscle, which included Proteinase K di-
gestion and DNase treatment (Qiagen 74104, 19131,
and 79254). Using 500 ng of total RNA as template,
cDNA was prepared by reverse transcriptase reac-
tion using the ABI high capacity cDNA archive kit
(ABI 4322171; Applied Biosystems, Foster City, CA,
USA). mRNA expression was assessed by real-time PCR
(RT-PCR) method using Applied Biosystems TaqMan
Assays-on-DemandTM Gene Expression Products (Ap-
plied Biosystems). Assays-on-DemandTM are a compre-
hensive collection of predesigned primer and probe sets
available “off the shelf” and each assay consists of 2 unla-
beled PCR primers and a FAMTM dye-labeled TaqMan
MGB probe. PCR was performed on the MJ Research
Opticon 2 (Bio-Rad, Inc., Waltham, MA, USA) instru-
ment. Negative controls for RT-PCR included reactions
containing no template. The amount of target gene in
ESRD patients was normalized to an endogenous con-
trol (GAPDH) and to the mRNA level in the controls
[17]. Data from the RT-PCR experiment can be analyzed
for absolute or relative quantification. Absolute quan-
tification determines the input copy number of the tran-
script of interest, usually by relating the PCR signal to
a standard curve. Relative quantification describes the
change in expression of gene relative a reference group,
such as an untreated control or a sample at time zero in
a time-course study. Quantifying the relative changes in
gene expression using real-time can be performed using
2-CT method [18].
Briefly, data from RT-PCR were imported into an Excel
spread sheet and analyzed using the following equation:
CT = (CT Target—CT GAPDH)Time x
− (CT Target—CT GAPDH)Time0.
CT is the fractional cycle number at which the amplified
target reaches a fixed threshold, CT is the difference on
threshold cycles for target and reference, cTimex is the time
point of interest, and Time0 represents the 1x expression
of the target gene normalized to GAPDH.
Immunohistochemical staining for IL-6 protein
We used modified immunohistochemistry method of
Zamora et al[19] to detect the IL-6 in the muscle biop-
sies. Briefly, the sections were rehydrated and incubated
with 5% Triton-X (Sigma-Aldrich, St. Louis, MO, USA)
for 10 minutes and then washed twice with 0.02 mol/L
phosphate-buffered saline (PBS). After blocking the sec-
tions in 5% goat serum, they were incubated overnight
with the primary rabbit IL-6 antibody (R&D Systems) in
a 1:20 dilution in 1% sheep serum at 4◦C. The following
data, sections were washed 5 times with PBS, the sec-
tions were incubated with secondary antibody labeled
with fluroscein isothiocyanate (FITC; R&D Systems).
Sections were mounted, visualized, and photographs
(EFD-3; Nikon, Japan) taken after excitation for 30 sec-
onds using the filter for FITC. We did not quantify the
fluorescence.
Statistics
Data are given as mean and standard error of mean
(SEM). a was set at 0.05. Paired and unpaired t test were
used when applicable. Repeated measures of analysis of
variance (ANOVA) were used with pre-, mid-, and end-
HD as the repeating factors and ESRD versus control as
the grouping factor with a post-hoc Tukey test. Simple
linear regression analysis was used to identify the associ-
ation between variables.
RESULTS
The etiology of ESRD was hypertension in 2, diabetic
nephrolpathy in 6, glomerulonephritis in 3, interstitial
nephropathy in 2, and unknown in 4. There were 4 di-
abetics among controls. Hemoglobin concentration was
significantly lower in ESRD patients (Table 1). The gly-
cated hemoglobin (HbA1C) levels in ESRD patients and
controls subjects with diabetes were 7.4 ± 0.3% and 7.7 ±
0.4%, respectively. ESRD patients were adequately dia-
lyzed, as evidenced by a urea reduction ratio of 72.0 ±
1.5%. Negative acute phase protein, serum albumin, was
higher, and positive acute phase proteins fibrinogen and
C-reactive protein (CRP) were lower in controls com-
pared to ESRD patients.
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Table 1. Clinical and biochemical data of the subjects
Control Pre-HD End-HD
Age years 46.2 ± 5.1 44 ± 5.4
Diabetics% 4 (44.4) 6 (35.3)
Weight kg 79.3 ± 12.6 75.2 ± 5.5
Hemoglobin g/dL 14.6 ± 0.2a 11.9 ± 0.3 12.0 ± 0.4
BUN mg/dL 14.9 ± 1.0 60.9 ± 4.0b 17.1 ± 1.6
Creatinine mg/dL 0.93 ± 0.05 9.29 ± 0.58b 5.09 ± 0.35
Glucose mg/dL 112.2 ± 11.3 108.5 ± 9.2 105.0 ± 6.3
Bicarbonate mEq/L 24.3 ± 0.6 23.2 ± 0.8 24.9 ± 1.5
Albumin g/dL 4.0 ± 0.1a 3.5 ± 0.1 3.6 ± 0.1
Fibrinogen g/dL 275.3 ± 12.5a 328.7 ± 28.6 402.7 ± 32.1
CRP mg/dL 1.10 ± 0.21a 3.74 ± 0.74 4.24 ± 1.03
Insulin lU/dL
Diabetics 23.6 ± 3.7d 31.1 ± 3.8d 26.4 ± 2.1d
Nondiabetics 5.5 ± 1.7 12.9 ± 1.2 10.2 ± 1.3
Glucagon pg/dL
Diabetics 97.6 ± 19.3 156.1 ± 25.6 98.0 ± 27.4
Nondiabetics 62.4 ± 11.4 117.9 ± 19.2 83.1 ± 10.9
Cortisol lg/dL 14.0 ± 2.9 10.8 ± 0.8 16.8 ± 1.5
Serum iron lg/dL 87.2 ± 6.4 76.6 ± 11.3
Ferritin ng/mL 306.1 ± 16.7 459.4 ± 53.8c
End-HD, samples obtained at the last 10 minutes of HD. Data expressed as
mean and SEM.
aP < 0.01 Control vs. pre-HD and HD.
bP < 0.001 Pre-HD vs. control and end-HD.
cP < 0.05 Pre-HD vs. control.
dDiabetics vs. nondiabetics P < 0.01.
Table 2. Plasma malonyldialdehyde (MDA) and carbonyl protein
(CP) concentrations in the artery and vein
Control Pre-HD Mid-HD End-HD
MDA pmol/mL
Artery 267.7 ± 14.7 325.5 ± 19.6a,b 299.5 ± 21.2 248.8 ± 16.1
Vein 281.3 ± 15.7c 340.6 ± 19.5a,b,d 285.8 ± 15.8d
CP nmol/mg protein
Artery 1.92 ± 0.05e 2.29 ± 0.09 2.18 ± 0.06 2.23 ± 0.07
Vein 1.91 ± 0.06e 2.29 ± 0.07 2.34 ± 0.08c
End-HD, samples obtained at the last 10 minutes of HD. Data expressed as
mean and SEM. MDA and CP were not measured at Mid-HD in the venous
samples.
aPre-HD vs. control, P < 0.03.
bPre-HD vs. end-HD, P < 0.001.
cArtery vs. vein, P < 0.01.
dArtery vs. vein, P < 0.001.
eControl vs. pre-HD and end-HD, P < 0.01.
Concentrations of MDA in the artery and vein
were significantly elevated in ESRD patients pre-HD
compared to controls, but were decreased during HD
(P < 0.001) (Table 2). Dialysis clearance of MDA was
16.9 ± 3.1 mL/min. MDA concentration in the vein was
higher than that in artery in both ESRD and control sub-
jects (P < 0.01). In ESRD patients (pre-HD and end-
HD), the concentration of CP in the artery and vein was
higher compared to controls (P < 0.01). While the CP
concentration in the artery did not change intradialysis,
it increased in the vein (P < 0.01). CP was not detected
in the dialysate.
Plasma cytokines in the artery and vein increased to a
varying degree during dialysis treatment (Table 3). How-
ever, the magnitude of increase in IL-6 intradialysis was
significantly higher in the vein than that observed in the
Table 3. Arterio-venous balance of cytokines in ESRD patients
Control Pre-HD Mid-HD End-HD
IL-1 pg/dL
Artery 0.98 ± 0.12 1.14 ± 0.06 1.19 ± 0.06 1.45 ± 0.09a
Vein 0.97 ± 0.10 1.19 ± 0.08 1.26 ± 0.05b 1.44 ± 0.10a
IL-6 pg/dL
Artery 2.94 ± 0.76 4.40 ± 0.41 5.14 ± 0.60b 11.29 ± 2.17c
Vein 3.24 ± 0.82 5.23 ± 0.59 6.94 ± 0.85bd 16.27 ± 2.42cd
IL-10 pg/dL
Artery 1.31 ± 0.22 0.80 ± 0.10 1.08 ± 0.20 1.98 ± 0.24e
Vein 1.29 ± 0.27 0.93 ± 0.14 1.13 ± 0.18 2.14 ± 0.26c
TNF-a pg/dL
Artery 0.64 ± 0.13 0.97 ± 0.07 0.96 ± 0.08 1.02 ± 0.11f
Vein 0.62 ± 0.14 1.02 ± 0.08 1.04 ± 0.09 1.20 ± 0.18f
End-HD, samples obtained at the last 10 minutes of HD. Data expressed as
mean and SEM.
aEnd-HD vs. pre-HD and control, P < 0.01.
bMid-HD vs. control, P < 0.05.
cEnd-HD vs. pre-HD, mid-HD, and control, P < 0.001.
dArtery vs. vein, P < 0.01.
eEnd-HD vs. pre-HD and mid-HD, P < 0.001.
fEnd-HD vs. control, P < 0.05.
artery. mRNA levels of IL-6 (0.028 ± 0.02 vs. 6.69 ± 0.21),
HO-1 (0.96 ± 0.01 vs. 5.08 ± 1.11), and SOCS-2 (0.63 ±
0.12 vs. 0.82 ± 0.14) in the muscle increased during HD
(P < 0.01) (Fig. 1). The changes in the mRNA levels of IL-
1b (0.065 ± 0.019 vs. 0.542 ± 0.328) and TNF-a (0.287 ±
0.62 vs. 0.796 ± 0.351) during dialysis were not significant.
IL-10 mRNA was not detectable in the muscle. Immuno-
histochemical staining for IL-6 protein was performed
in multiple 10 lm sections obtained from 2 ESRD pa-
tients (pre-HD and end-HD) and 2 controls. IL-6 protein
expression in the muscle was increased in samples ob-
tained at the end of HD compared to pre-HD and con-
trols (Fig. 2). Net increase in the IL-6 concentration in
the vein, as indicated by the arterio-venous balance stud-
ies, correlated positively with IL-6 mRNA (r2 = 0.29, P <
0.01). mRNA levels of IL-6 and HO-1 were positively and
significantly correlated (r2 = 0.41, P < 0.001).
MDA (348.2 ± 32.0 vs. 288.6 ± 24.7 pmol/mL), CP
(2.38 ± 0.15 vs. 2.18 ± 0.08 nmol/mg protein), IL-1 (1.15 ±
0.08 vs.1.05 ± 0.07 pg/dL), IL-6 (4.65 ± 0.64 vs. 4.08 ±
0.44 pg/dL), IL-10 (0.87 ± 0.16 vs. 0.79 ± 0.09 pg/dL),
and TNF-a (0.87 ± 0.05 vs. 1.07 ± 0.10 pg/dL) in the
artery pre-HD among patients with and without diabetes
were not significantly different. The changes at mid- or
end-HD, or the arterio-venous differences in the plasma
concentration of these biomolecules, were comparable
between the 2 groups. The mRNA levels were also not
significantly different.
DISCUSSION
In the present study, we measured the A-V balance of
cytokines and markers of oxidative stress, and also genes
involved in the regulation of inflammatory response and
oxidative stress in ESRD patients and healthy volunteers.
The arterial concentration of MDA decreased during HD
































Fig. 1. Interleukin-6 (IL-6) and
hemeoxygenase-1 (HO-1) and suppres-
sors of cytokine signaling-2 (SOCS-2) gene
expression in the skeletal muscle were
increased during hemodialysis (HD). Rela-
tive change in mRNA expression (2-Ct
method). Pre-HD, before HD; mid-HD,
midpoint of HD; end-HD, last 10 minutes
of HD. ¶End-HD vs. pre-HD, P < 0.05;
†Pre-HD vs. mid-HD, P < 0.05; ‡Pre-HD vs.
mid-HD, P < 0.01; ∗End-HD vs. pre-HD and
mid-HD, P < 0.001.
because of loss in the dialysate. CP level in the artery did
not change significantly during HD because it was not
removed by dialysis. A-V balance studies showed that
there is a net increase in the concentrations of MDA,
CP, and IL-6 in the femoral vein during HD that was
accompanied by an increase in the mRNA levels of IL-6,
HO-1, and SOCS-2 in the skeletal muscle. These results
suggest that skeletal muscle may be an important source
of oxidative stress and IL-6 during HD. Femoral arterio-
venous difference has been used as an estimate of release
of biomolecules from the leg muscle [20, 21].
Cytokines are pleiotropic polypeptides with molecular
weight ranging from 10 to 45 kD that are produced by
different cells in response to diverse stimuli. Cytokines
may be pro- or anti-inflammatory. The production of
proinflammatory cytokines is controlled by the regula-
tory cytokine, IL-10. While IL-1 and TNF-a are classified
as proinflammatory cytokines, IL-6 has both pro- and
anti-inflammatory properties [22]. In vitro and in vivo
data support the hypothesis that cytokines are released
by PBMCs intradialysis. We observed that the concen-
trations of cytokines increased both in the artery and
vein during dialysis, indicating increased generation of
cytokines intradialysis. The magnitude of increase in the
concentration of IL-6 in the femoral vein was significantly
higher than that in the artery during HD, possibly due to
net release from the leg compartment. This is supported
by the increase in gene expression of IL-6 in the skeletal
muscle during HD. IL-6 is expressed in the human skele-
tal muscle [23], and skeletal muscle is capable of releasing
this protein [20, 23]. Release of IL-6 is mainly regulated by
local stimuli [20], and preliminary studies suggest that it
may not be a marker of muscle damage [24, 25]. However,
−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−→
Fig. 2. Immunohistochemical staining for IL-6 in the muscle. Increased
fluorescence was observed in samples obtained at the end of HD com-
pared with pre-HD and controls.
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we demonstrated that IL-6 induces expression of genes
regulating protein catabolism [26], increases muscle pro-
tein breakdown [27], and facilitates acute phase protein
synthesis [28] during HD. Investigators have shown that
muscle derived IL-6 functions as an exocrine hormone
during exercise, exerting an effect on the liver and adi-
pose tissue, thereby maintaining glucose homoeostasis
[29]. We did not find any significant changes in insulin,
glucagons, or glucose levels during HD. While previous
investigators have demonstrated that PBMCs are the pri-
mary source of cytokines during HD, this study suggests
that IL-6 may be released from the skeletal muscle also.
Increased plasma IL-6 could augment its own gene ex-
pression in the muscle through autocrine mechanism [30].
It is possible that increased cytokine released from PBMC
facilitates the IL-6 gene expression in the muscle. Ev-
idence from our laboratory indicates that the cytokine
gene expression is not increased locally in the muscle in
response to trauma related to biopsy up to 6 hours (un-
published data). While it is true that skeletal myocytes can
express IL-6, the contribution from mononuclear cell in-
filtrates and vascular smooth muscle cells (VSMC) in the
biopsy samples cannot be discounted [31, 32]. HD has a
variable effect on plasma endothelin-1 (ET-1) concentra-
tion [33]. Investigators have demonstrated that ET-1 in-
creases IL-6 mRNA levels in human VSMC [32]. ESRD
patients with diabetes are metabolically different from
those without diabetes. However, since the same patient
is studied before and during HD, the impact of diabetic
status on the results of the study probably minimal.
There is a bidirectional relationship between cytokines
and oxidative stress. Exposure of myotubes to ROS
producing agents results in an increase in IL-6 release
through the activation of the redox sensitive transcrip-
tion factor, NF-jB [11]. Oxygen derived free radicals are
produced during mitochondrial metabolism by the uni-
valent reduction of O2 to water. Oxidative stress is mea-
sured by detection of various modified macromolecules
that are generated from the ROS because they them-
selves have half-lives of just a few seconds. The analysis
of oxidative stress during HD is further complicated by a
number of factors in vivo, including changes in generation
rate, size of the extracellular compartment, intercompart-
mental flux, and depuration by dialysis. PBMCs are acti-
vated by contact with nonbiological surface during HD,
leading to NADPH-dependent production of superoxide
and other reactive oxygen intermediates [34]. Prelimi-
nary evidence indicates that mitochondrial function and
energy production via oxidative metabolism is impaired
in ESRD [35]. In our study, while the concentration of
MDA in the vein was higher than that in the artery in
controls (5.4%) and ESRD patients pre-HD (5.0%), the
magnitude of increase was more profound intradialysis
(17.8%). Despite increased generation, the concentration
of MDA decreased by 23% in the artery during dialysis
due to loss in the dialysate. Using different techniques, in-
vestigators have demonstrated that uremic plasma accu-
mulates oxidants, which are freely dialyzable [6, 36]. The
plasma levels of MDA and thiobarbituric acid reactive
substances (TBARS) are reported to decrease by 25%
to 88% during HD [6, 37]. Similar to our study, Schettler
et al [38] observed that while the arterial concentration
of TBARS decreased (4%), the venous concentration in-
creased (6%) intradialysis. Because of the larger molecu-
lar size, CP is not removed by HD and, hence, the arterial
concentration did not decrease during HD. Dissociation
between the plasma levels of different markers of oxida-
tive stress has been reported pre- [6] and intradialysis [38]
by other researchers also. A-V balance showed that the
concentration of CP in the vein increased by 5.1%. While
this study does not define the role of blood membrane in-
teraction in increased oxidative stress during HD, these
results suggest that skeletal muscle may also be an impor-
tant source of oxidative stress in ESRD.
We observed that the HO-1 mRNA level increased
during HD. Heme oxygenase system is involved in many
physiologic as well as pathophysiologic processes, such as
cytoprotection, apoptosis, and inflammation. HO is the
rate limiting enzyme in the catabolism of heme. Three
isoforms of HO have been identified (HO-1, HO-2, and
HO-3). Under physiologic conditions, most cells express
low or undetectable levels of HO-1 protein, whereas
HO-2 proteins are constitutively expressed. HO-3 awaits
further characterization. Cytokines and ROS have been
demonstrated to induce HO-1 expression [39], and it is
speculated that HO-1 is important in the resolution of
acute inflammation [40]. Increase in IL-6 mRNA level
during HD was accompanied by increase in SOCS-2 gene
expression. IL-6 induces marked increase in expression
of CIS, SOCS-1, SOCS-2, and SOCS-3 in tissues, which
in turn result in inhibition of signaling of wide range of
cytokines [41]. Because SOCS genes are induced by cy-
tokines and the corresponding proteins inhibit further
cytokine-induced signaling, SOCS proteins are believed
to form part of classic negative feedback loop mechanism.
Loss of lean body mass is an important predictor of
mortality and morbidity in ESRD. While malnutrition is
touted as a cause of uremic sarcopenia, muscle wasting
has been described even in well-nourished patients on
hemodialysis, indicating that factors other than malnu-
trition may contribute to uremic cachexia. Inflammation
and oxidative stress coexist in ESRD and may contribute
to muscle wasting through mitochondrial dysfunction
[42]. The results from this study demonstrate that there
is net release of MDA, CP, and IL-6 in to the vein during
HD, possibly from skeletal muscle. This is supported by
the increase in IL-6, HO-1, and SOCS-2 mRNA levels in
the skeletal muscle during HD. Thus, skeletal muscle may
contribute to the increase in plasma IL-6 and oxidative
stress during HD.
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